TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Publication Type:

Journal Article


British journal of haematology, Volume 147, Issue 3, p.347-51 (2009)


2009, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Center-Authored Paper, Follow-Up Studies, Gene Deletion, Humans, Multiple Myeloma, Prognosis, Public Health Sciences Division, Pyrazines, Survival Analysis, Treatment Outcome, Tumor Suppressor Protein p53


Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3- translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo-insufficiency also did not compromise, in the 83% with genomically defined low-risk myeloma, survival or event-free survival. FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent.